8-K: Candel Therapeutics' CAN-2409 Shows Positive Phase 3 Results in Prostate Cancer, to be Presented at ASCO 2025

Candel Therapeutics announces positive Phase 3 clinical trial results for CAN-2409 in localized prostate cancer, demonstrating a statistically significant improvement in disease-free survival.

Summary

• Candel Therapeutics announced that positive results from its Phase 3 clinical trial of aglatimagene besadenovec (CAN-2409) in patients with intermediate-to-high-risk localized prostate cancer will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
• The Phase 3 trial met its primary and secondary endpoints, demonstrating a statistically significant improvement in disease-free survival (DFS) with a p-value of 0.0155.
• Patients who received CAN-2409 (n=496) experienced a 30% reduction (HR 0.7) in the risk of prostate cancer recurrence or death compared to placebo (n=249).
• The results were initially announced in December 2024.
• CAN-2409 led to a significantly higher rate of pathological clinical response in two-year biopsy samples compared to placebo, indicating potential elimination of cancer at the microscopic level.
• The company anticipates submitting a Biologics License Application (BLA) for CAN-2409 in the fourth quarter of 2026.

Sentiment

Score: 8

Explanation: The document presents positive Phase 3 clinical trial results, indicating a significant improvement in disease-free survival for prostate cancer patients. The management's comments are optimistic, and the presentation at ASCO 2025 further validates the findings. However, as with all clinical-stage biopharmaceutical companies, there are inherent risks associated with regulatory approvals and future development.

Positives

• The Phase 3 clinical trial met its primary and secondary endpoints.
• CAN-2409 showed a statistically significant improvement in disease-free survival.
• The treatment was generally well-tolerated, with a low incidence of treatment-related serious adverse events.
• CAN-2409 led to a significantly higher rate of pathological clinical response in two-year biopsy samples compared to placebo.
• Significant increase in the proportion of patients achieving a prostate-specific antigen (PSA) nadir (<0.2 ng/ml) was observed in the treatment arm compared to the placebo control arm (67.1% vs. 58.6%, respectively; p=0.0164).

Risks

• The forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially.
• Final data from preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials.
• The company's ability to obtain and maintain regulatory approval of product candidates is not guaranteed.

Future Outlook

Candel Therapeutics anticipates submitting a Biologics License Application (BLA) for CAN-2409 in the fourth quarter of 2026 and remains focused on bringing this potentially transformative treatment to patients.

Management Comments

• 'The improvement in disease-free survival shown in this trial is not only statistically significant, but also clinically meaningful,' stated Glen Gejerman, M.D., MBA, Co-Director of Urologic Oncology at Hackensack Meridian Health.
• Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel, said, 'We are honored that our pivotal phase 3 CAN-2409 data will be presented at the ASCO Annual Meeting, reinforcing the strength of our previously announced results.'

Industry Context

The announcement highlights a potential advancement in the treatment of intermediate-to-high-risk localized prostate cancer, an area with significant unmet need, as approximately 30% of patients experience disease recurrence following radical prostatectomy or radiotherapy.

Comparison to Industry Standards

• The press release states that this is the first multicenter, randomized phase 3 trial in over 20 years to meet both primary and secondary endpoints in localized prostate cancer.
• This suggests that CAN-2409's results are a significant improvement over existing treatments and could potentially redefine the standard of care for this patient population.
• It is difficult to make a direct comparison without knowing the specific details of other trials, but the fact that this trial met both primary and secondary endpoints is a positive sign.

Stakeholder Impact

• Positive results could lead to improved treatment options for prostate cancer patients.
• Successful BLA submission could increase shareholder value.
• The company's employees may benefit from the company's success.

Next Steps

• Presentation of Phase 3 CAN-2409 data at the ASCO Annual Meeting from May 30 to June 3, 2025.
• Submission of a Biologics License Application (BLA) for CAN-2409 in the fourth quarter of 2026.

Key Dates

Keywords

CAN-2409, prostate cancer, clinical trial, disease-free survival, immunotherapy, Candel Therapeutics, ASCO 2025, aglatimagene besadenovec